IMPLANET: 2014 annual revenue: €7.0 million

Strong revenue growth in 2014 (excluding Hip activity): +28% to €6.3 million

Significant increase in Spine activity: +138%

US sales exceed $1 million

Record number of JAZZ implants sold in 2014: >4,200 (2.3 x)

BORDEAUX, France & BOSTON--(BUSINESS WIRE)--Regulatory News:

IMPLANET (Paris:IMPL) (Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants, today announces its revenue for the 4^th quarter and full year to 31 December 2014.

Ludovic Lastennet, CEO of Implanet, states: “We have delivered the ambitious targets we had set, and ended 2014 with particularly high growth levels in all strategic activities. The 2014 focus on sales expansion in new countries and markets should enable us to accelerate growth of the Knee and Spine segments, beginning in early 2015. By exceeding 1 million dollars in sales in its very first year, our American subsidiary has achieved substantial results in a market that is just now discovering our JAZZ implant. The steady acceleration of JAZZ sales in France, the United States and the rest of the world generated growth of +138%, with 4,260 implants sold in 2014. This illustrates the quality of our sales teams, our sales partners and our strategic approach. Backed by a firmly established organization, a 25-agency sales network in the United States and a relevant economic proposal, we will do our utmost to further this dynamic in 2015. We are now, more than ever, convinced that the sublaminar implant is on the verge of becoming the global benchmark in the surgical treatment of major deformity, and will henceforth strive to prove its efficiency in the field of degenerative bone disorders.”

Revenue (in € thousands - IFRS)	2014	2013	Change
1^st quarter revenue	2,047	1,918	+7%
2^nd quarter revenue	1,954	1,399	+40%
3^rd quarter revenue	1,188	1,645	-28%
Spine	658	243	+171%
Knee + Arthroscopy	1,190	1,049	+14%
Hip	-	437	-
Total 4^th quarter revenue	1,848	1,728	+7%
Spine	1,930	811	+138%
Knee + Arthroscopy	4,342	4,086	+6%
Hip	765	1,793	-57%
Annual revenue	7,037	6,690	+5%

4Q 2014: growth of +43% (excluding Hip activity), Spine sales multiplied by 2.7

Over the 4^th quarter, Implanet recorded revenue of €1,848 thousand, up +7% (vs. €1,728 thousand in 4Q 2013). Excluding Hip activity, Implanet recorded strong growth of +43% over the quarter. Export sales totaled €1,030 thousand over the quarter (56% of 4Q 2014 revenue), including €427 thousand from the United States (23% of 4Q 2014 revenue).

Over the final quarter, Spine activity sales were multiplied by 2.7 and totaled €658 thousand (vs. €243 thousand in 4Q 2013). Over the quarter, Implanet sold a total of 1,196 JAZZ implants (vs. 593 in 4Q 2013), with more than 170 operations carried out. Furthermore, the Company continued its momentum in the Knee segment with revenue growth of +6% to €4,342 thousand (vs. €4,086 thousand).

2014 annual revenue: sharp acceleration in sales across all markets

In FY 2014, Implanet recorded revenue growth of €7,037 thousand, up +5% (vs. €6,690 thousand), impacted by its withdrawal from Hip activity (which contributed €765 thousands to 2014 revenue vs. €1,793 thousand to 2013 revenue). Excluding Hip activity, Implanet generated substantial revenue growth of +28% in 2014. In France, annual sales totaled €3,985 thousand (57% of 2014 revenue). Export sales totaled €3,052 thousand (43% of 2014 revenue), with continued growth of the American subsidiary with sales of €821 thousand (12% of 2014 revenue). In 2014, a total of more than 600 operations were carried out using the JAZZ implant.

This 2014 performance reflects the acceleration in the adoption by spine surgeons of the JAZZ technological platform: Sales were multiplied by 2.4 compared with the previous year, totaling €1,930 thousand (vs. €811 thousand in 2013). Implanet sold 4,260 JAZZ implants (vs. 1,829 in 2013), an increase of +133% by volume. In total, more than 6,000 implants have been sold since the launch of JAZZ, including >2,800 in France, >850 in the United States and >2,350 in the rest of the world.

2014 Knee activity sustained its positive momentum with revenue growth of €4,342 thousand, up +6% (vs. €4,086 thousand), validating the strategic importance of the general orthopedic platform and the continued pursuit of its development, both in France and abroad.

Significant milestones and events: a year of many successes

Since the start of 2014, Implanet has continued to implement the business plan announced at the time of its IPO, with a number of major achievements:

Maximize JAZZ adoption

• Publication of a study regarding the restoration of frontal and sagittal alignments in adolescent scoliosis surgery;
• Publication of a study showing the efficiency of JAZZ implanted in the vertebrae of patients with degenerative bone pathologies;
• Encouraging preliminary results from an in-vitro biomechanical study in osteoporotic specimens completed by the Mayo Clinic.

Product range extension

• Development of the JAZZ technological platform;
• Adaptation of JAZZ to various existing rod sizes;
• Harmonization of the CE and FDA regulatory files for the entire range;
• Validation of a first generation of instruments for less-invasive surgery.

Large-scale commercial deployment

• Acceleration in the United States with the signing of 25 sales partner contracts along with significant strengthening of the Management Team (3 Sales Directors, 1 Marketing and Training Director, 2 Independent Board Members and 1 Medical Advisor);
• Structuring the rest of the world sales team: 1 European Sales Director, 1 International Product Officer and 1 Training Officer.

About IMPLANET

Founded in 2007 and based near Bordeaux, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surge Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 45 staff and recorded 2014 sales of €7.0 million. For further information, please visit www.implanet.com.

IMPLANET is listed on Compartment C of Euronext™ Paris.
Ticker: IMPL - ISIN code: FR0010458729